Position in PRME
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$2,394,588
-$2,455,212 QoQ
Shares Held
648,940
-53.4% QoQ
Ownership
0.358%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#31
of 186 holders
Holding Since
Mar 2024
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in PRME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026D. E. Shaw & Co., Inc. holds $5,017,559,982 across 217 Biotechnology names. PRME ranks #124 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
|
5,877,959 | $626,707,987 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,104,109 | $332,369,932 | |
| 3 | EXEL |
Exelixis, Inc.
|
5,551,747 | $302,070,554 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
3,633,007 | $270,586,360 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
3,400,808 | $186,840,390 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
2,006,479 | $157,047,110 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
604,753 | $148,025,391 | |
| 8 | PTCT |
Ptc Therapeutics, Inc.
|
1,548,919 | $126,345,322 |
All Filings in PRME
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,394,588 | 648,940 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $4,849,800 | 1,393,621 | Shares | Defined | 2026-05-15 | |
| 2025-12-31 | $5,383,249 | 1,551,369 | Shares | Defined | 2026-02-17 | |
| 2025-09-30 | $12,275,820 | 2,215,852 | Shares | Defined | 2025-11-14 | |
| 2024-09-30 | $539,675 | 139,451 | Shares | Defined | 2024-11-14 | |
| 2024-06-30 | $233,535 | 45,435 | Shares | Defined | 2024-08-14 | |
| 2024-03-31 | $186,676 | 26,668 | Shares | Defined | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||